Alberta Investment Management Corp Grows Position in Johnson & Johnson (NYSE:JNJ)

Alberta Investment Management Corp boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 770.6% during the 4th quarter, Holdings Channel.com reports. The firm owned 127,976 shares of the company’s stock after buying an additional 113,276 shares during the quarter. Alberta Investment Management Corp’s holdings in Johnson & Johnson were worth $18,508,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently bought and sold shares of the stock. Summit Place Financial Advisors LLC lifted its position in Johnson & Johnson by 0.5% during the fourth quarter. Summit Place Financial Advisors LLC now owns 18,248 shares of the company’s stock valued at $2,639,000 after purchasing an additional 90 shares in the last quarter. Vista Capital Partners Inc. raised its holdings in Johnson & Johnson by 2.2% during the fourth quarter. Vista Capital Partners Inc. now owns 5,097 shares of the company’s stock valued at $737,000 after acquiring an additional 110 shares during the period. Pasadena Private Wealth LLC raised its holdings in Johnson & Johnson by 51.8% during the fourth quarter. Pasadena Private Wealth LLC now owns 2,251 shares of the company’s stock valued at $326,000 after acquiring an additional 768 shares during the period. Hudson Value Partners LLC raised its holdings in Johnson & Johnson by 2.5% during the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company’s stock valued at $5,648,000 after acquiring an additional 1,022 shares during the period. Finally, Werba Rubin Papier Wealth Management raised its holdings in Johnson & Johnson by 3.3% during the fourth quarter. Werba Rubin Papier Wealth Management now owns 2,080 shares of the company’s stock valued at $301,000 after acquiring an additional 66 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Trading Up 1.7 %

Shares of NYSE JNJ opened at $162.35 on Friday. The business’s 50 day moving average is $148.93 and its two-hundred day moving average is $155.88. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. Johnson & Johnson has a 1-year low of $140.68 and a 1-year high of $168.85. The stock has a market capitalization of $390.87 billion, a P/E ratio of 24.41, a PEG ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. The company had revenue of $22.52 billion for the quarter, compared to analysts’ expectations of $22.44 billion. During the same period in the previous year, the firm posted $2.29 earnings per share. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. As a group, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.06%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 74.59%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on JNJ shares. Wolfe Research started coverage on Johnson & Johnson in a report on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Royal Bank of Canada reissued an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a report on Wednesday. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 25th. Argus raised Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Finally, Bank of America reduced their target price on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating on the stock in a report on Thursday, January 23rd. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of the company’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total value of $62,928.45. Following the transaction, the executive vice president now owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.